Mineralys Therapeutics, Inc.
MLYS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $218 | $102 | $165 | $114 |
| Short-Term Investments | $0 | $223 | $178 | $84 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $382 | $10 | $11 | $7 |
| Total Curr. Assets | $600 | $335 | $355 | $205 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $600 | $336 | $355 | $206 |
| Liabilities | – | – | – | – |
| Payables | $1 | $3 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $22 | $19 | $13 | $14 |
| Total Curr. Liab. | $24 | $22 | $13 | $15 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $24 | $22 | $13 | $15 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$425 | -$388 | -$345 | -$303 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,001 | $702 | $686 | $494 |
| Total Equity | $576 | $314 | $342 | $191 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $600 | $336 | $355 | $206 |
| Net Debt | -$218 | -$102 | -$165 | -$114 |